Company intelligence / Profile preview

Paindrainer

Ownership: Private
Development stage: Other

Overview

Three completed clinical studies have demonstrated that the investigational version of Paindrainer PD1 leads to improved quality of life and reduced pain in patients with chronic pain when used regularly over a period of 12 weeks. The solution is FDA registered as a Class I Medical Device, has been validated in both Scandinavian and US hospital settings, and is currently being commercialized in partnership with healthcare providers.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapyDigital therapeutic
Industry: Digital Health Medical Devices

Partnerships

Dr. Edward Rubin, past President of The New York Society of Interventional Pain Physicians (commercial partnership for US market entry)Complete Care Partner/Complete Care Partners (access to >70 healthcare providers)

Beyond the preview

Go deeper on Paindrainer.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paindrainer.

Explore the full profile